Production and characterization of antibodies to platelet-activating factor.
Antibodies directed against platelet-activating factor (PAF) have been raised in rabbits immunized with a novel platelet-activating factor analogue-conjugate. An analogue of PAF with a carbon double bond at the terminal end of the alkyl chain was subjected to ozonolysis and converted to the aldehyde. The aldehyde was coupled to thyroglobulin by reductive alkylation and rabbits were immunized via either intramuscular or intradermal routes in complete Freund's adjuvant. The antibodies are specific for PAF with a preference for the optically active (R)-enantiomer. There appears to be a requirement for antibody binding of an alkyl chain of up to 18 Carbon atoms at C1, and an acetyl group in the C2 position. The ability of a number of structural analogues to inhibit binding of tracer to the antibody is related to the biological activity of the analogue, and therefore may reflect the structural domains that are critical for PAF to interact with its receptor.
Macpherson
J L
JL
School of Medicine, University of New South Wales, Kogarah, Australia.
Spur
B
B
Pyne
S G
SG
Heymans
F
F
Cox
M F
MF
Godfroid
J J
JJ
Krilis
S A
SA
D000818:Animals; D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation; D000918:Antibody Specificity; D001666:Binding Sites, Antibody; D066298:In Vitro Techniques; D010972:Platelet Activating Factor / Q000031:analogs & derivatives / Q000032:analysis / Q000276:immunology* / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D011863:Radioimmunoassay; D013329:Structure-Activity Relationship
D000906:Antibodies; D010972:Platelet Activating Factor